AKO 001
Alternative Names: AKO-001Latest Information Update: 08 Mar 2022
At a glance
- Originator Akome Biotech
- Developer Akome Biotech; Complutense University Madrid
- Class Dimethylamines; Drug withdrawal therapies; Indoles; Neuropsychotherapeutics; Organophosphorus compounds; Small molecules; Tryptamines; Vascular disorder therapies
- Mechanism of Action Apoptosis stimulants; Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Stroke
Most Recent Events
- 04 Mar 2022 Preclinical trials in Stroke in Spain
- 03 Mar 2022 Akome Biotech and Universidad Complutense de Madrid agree to co-develop psychedelic compounds for the treatment of Alzheimer's disease, Parkinson's disease, major depressive disorder and ischaemic stroke
- 07 Aug 2021 Akome Biotech plans a clinical trial of AKO 001 for Stroke